TWI362265B - Anti-cancer agent containing 帢-帢-帢-trifluorothymidine and thymidine phosphorylase inhibitor in combination - Google Patents

Anti-cancer agent containing 帢-帢-帢-trifluorothymidine and thymidine phosphorylase inhibitor in combination Download PDF

Info

Publication number
TWI362265B
TWI362265B TW095103114A TW95103114A TWI362265B TW I362265 B TWI362265 B TW I362265B TW 095103114 A TW095103114 A TW 095103114A TW 95103114 A TW95103114 A TW 95103114A TW I362265 B TWI362265 B TW I362265B
Authority
TW
Taiwan
Prior art keywords
drug
ftd
day
divided
cancer
Prior art date
Application number
TW095103114A
Other languages
English (en)
Chinese (zh)
Other versions
TW200637562A (en
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI362265(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TW200637562A publication Critical patent/TW200637562A/zh
Application granted granted Critical
Publication of TWI362265B publication Critical patent/TWI362265B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095103114A 2005-01-26 2006-01-26 Anti-cancer agent containing 帢-帢-帢-trifluorothymidine and thymidine phosphorylase inhibitor in combination TWI362265B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06

Publications (2)

Publication Number Publication Date
TW200637562A TW200637562A (en) 2006-11-01
TWI362265B true TWI362265B (en) 2012-04-21

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095103114A TWI362265B (en) 2005-01-26 2006-01-26 Anti-cancer agent containing 帢-帢-帢-trifluorothymidine and thymidine phosphorylase inhibitor in combination

Country Status (20)

Country Link
EP (1) EP1849470B2 (2)
JP (1) JP5576591B2 (2)
KR (1) KR101468216B1 (2)
AU (1) AU2006209547C1 (2)
BE (1) BE2017C028I2 (2)
CA (1) CA2594713A1 (2)
CY (2) CY1119393T1 (2)
DK (1) DK1849470T4 (2)
ES (1) ES2630002T5 (2)
FI (1) FI1849470T4 (2)
FR (1) FR17C1028I2 (2)
HU (2) HUE033306T2 (2)
LT (2) LT1849470T (2)
LU (1) LUC00036I2 (2)
NL (1) NL300889I2 (2)
PL (1) PL1849470T5 (2)
PT (1) PT1849470T (2)
SI (1) SI1849470T2 (2)
TW (1) TWI362265B (2)
WO (1) WO2006080327A1 (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2587381T3 (es) 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
JP2011520845A (ja) * 2008-05-15 2011-07-21 カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー 抗癌剤の組合せによる治療
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
HUE035347T2 (en) 2011-08-16 2018-05-02 Taiho Pharmaceutical Co Ltd Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150009540A (ko) * 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
RU2668125C2 (ru) * 2013-03-27 2018-09-26 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
KR101847252B1 (ko) * 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
US20160082032A1 (en) * 2013-05-17 2016-03-24 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
HRP20230523T1 (hr) 2013-09-06 2023-08-04 Taiho Pharmaceutical Co., Ltd. Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
JP6882205B2 (ja) 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
JP3088758B2 (ja) * 1996-09-24 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体を含有する癌転移抑制剤
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa

Also Published As

Publication number Publication date
JP5576591B2 (ja) 2014-08-20
HUE033306T2 (hu) 2017-11-28
AU2006209547B2 (en) 2011-05-26
EP1849470A4 (en) 2010-12-08
HUS1700032I1 (hu) 2017-09-28
CY2017029I1 (el) 2018-02-14
WO2006080327A1 (ja) 2006-08-03
LUC00036I2 (2) 2017-12-01
KR101468216B1 (ko) 2014-12-03
ES2630002T3 (es) 2017-08-17
RU2007132181A (ru) 2009-03-10
SI1849470T1 (sl) 2017-10-30
PL1849470T3 (pl) 2017-11-30
EP1849470B2 (en) 2024-03-20
LTPA2017024I1 (lt) 2017-08-10
TW200637562A (en) 2006-11-01
EP1849470B1 (en) 2017-06-21
NL300889I1 (nl) 2017-08-14
SI1849470T2 (sl) 2024-05-31
AU2006209547C1 (en) 2022-04-07
CA2594713A1 (en) 2006-08-03
JPWO2006080327A1 (ja) 2008-06-19
LT1849470T (lt) 2017-07-25
FR17C1028I2 (fr) 2018-11-02
PL1849470T5 (pl) 2024-06-10
LUC00036I1 (2) 2017-10-02
ES2630002T5 (es) 2024-09-19
NL300889I2 (nl) 2018-01-16
BE2017C028I2 (2) 2025-09-10
DK1849470T4 (en) 2024-04-02
LTC1849470I2 (lt) 2019-10-25
KR20070104559A (ko) 2007-10-26
PT1849470T (pt) 2017-09-22
EP1849470A1 (en) 2007-10-31
CY1119393T1 (el) 2018-02-14
FR17C1028I1 (2) 2017-09-29
FI1849470T4 (fi) 2024-03-22
CY2017029I2 (el) 2018-02-14
AU2006209547A1 (en) 2006-08-03
DK1849470T3 (en) 2017-08-14
RU2394581C2 (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
TWI362265B (en) Anti-cancer agent containing 帢-帢-帢-trifluorothymidine and thymidine phosphorylase inhibitor in combination
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
TWI594986B (zh) Antineoplastic agent effect enhancer
CA2634765A1 (en) Pharmaceutical composition containing histone deacetylase inhibitor
HK1201198A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
TWI426909B (zh) Radiation therapy enhancer
JP2021113228A (ja) 重度腎機能障害を有する癌患者に対する治療方法
TWI399206B (zh) 抗腫瘤劑
JP7142707B2 (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤
EP3957310A1 (en) Composition and use thereof in preparation of medication for treating cancer
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
TWI434700B (zh) 放射線治療增強劑
WO2003022290A1 (en) Medicinal compositions for diabetic neuropathy
MXPA05000451A (es) Composicion medicinal para neuropatia inducida por farmaco.
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
JP6063871B2 (ja) 組合せ
TW200846013A (en) Cytidine derivative-containing antitumor agent for continuous intravenous administration
JP2003300888A (ja) 抗腫瘍効果増強剤
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物